logo-loader
viewTRACON Pharmaceuticals

Full interview: TRACON Pharmaceuticals reveals its low-cost drug development efforts in its 4Q and FY results

TRACON Pharmaceuticals (NASDAQ:TCON) CEO Charles Theuer tells Proactive the biotechnology company ended 2019 with cash, cash equivalents and short-term investments of $16.4 million.

Theuer explains despite engaging in five different clinical trials, three of the five company's clinical trials are funded by its partners, allowing it to have a 1 year cash runway into 2020.

Quick facts: TRACON Pharmaceuticals

Price: 2.3 USD

NASDAQ:TCON
Market: NASDAQ
Market Cap: $12.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

TRACON Pharmaceuticals looks forward to positive Phase 2 cancer trial data...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive its corporate partners will present positive data from a Phase 2 cancer trial of the drug envafolimab at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. Theuer says the trial enrolled...

2 weeks, 2 days ago

2 min read